Le Lézard
Classified in: Health, Science and technology
Subject: Product/Service

LivaNova Announces Commercial Launch of Perceval Plus Aortic Heart Valve in Europe


LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced that the advanced Perceval® Plus sutureless surgical aortic heart valve is now available for commercial release in Europe, having successfully completed a one-year limited launch with initial real-world clinical data gathering. Perceval Plus is positioned to become an essential component to any comprehensive heart program. Building on the clinically proven experience with Perceval®, this next-generation valve facilitates minimally invasive cardiac surgery (MICS) and makes sutureless aortic valve replacement available to a wide patient population. Key innovations with Perceval Plus include the anticalcification treatment, FREE, for valve durability, along with design changes intended to improve patient outcomes.

"Continual innovation for tissue heart valves is important for two primary reasons. First, our patients have a longer life expectancy, so we have to provide them with valves that have solid long-term performance. Second, we are using tissue valves more and more frequently in relatively younger patients," said Prof. Bart Meuris, Head of Clinic of the University Hospital in Leuven, Belgium. "We have very good long-term clinical experience with the current Perceval platform,1 and we expect Perceval Plus to deliver even better long-term outcomes with the FREE anticalcification treatment."

Perceval Plus is the next generation of Perceval, which is a trusted technology with 13 years of clinical use and more than 50,000 implants worldwide. Key benefits of Perceval Plus are:

"We are already seeing very promising initial results with Perceval Plus, contributing to the strong body of evidence for Perceval," said Prof. Jens Wippermann, Clinical Director of the Cardio-thoracic surgery department at University of Magdeburg in Germany. "PPI has also been found to be substantially reduced with modified intraoperative approaches and an emphasis on proper valve sizing."1,2

The first Perceval Plus implant was performed in 2018 by Prof. Hermann Reichenspurner and Prof. Evaldas Girdauskas of the Department of Cardiothoracic Surgery at University Heart Center, Hamburg, Germany. After a limited commercial release in selected European centers and having secured two-year shelf life approval, Perceval Plus is now broadly available in CE Mark-dependent geographies.

"Through the innovations introduced with Perceval Plus and building upon the positive outcomes from the recent PERSIST-AVR clinical study, we are proud to deliver our next-generation sutureless surgical innovation to heart teams throughout Europe with the overall goal of improving patient outcomes," said Stephanie Bolton, LivaNova President, Europe.

For more information on Perceval Plus, visit the LivaNova website.

About LivaNova

LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 4,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. LivaNova operates as two businesses: Cardiovascular and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.), respectively.

For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains "forward-looking statements" concerning our goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding Perceval and Perceval Plus. Actual results may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, as supplemented by any risk factors contained in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. We undertake no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

References

  1. Szecel D, Meuris B. Long-term outcome with sutureless valves: 12 years of Perceval experience. Ann Cardiothorac Surg 2020. doi: 10.21037/acs.2020.04.03
  2. Meuris B, De Praetere H, Strasly M, Trabucco P, Lai J, Verbrugghe P, et al. A novel tissue treatment to reduce mineralization of bovine pericardial heart valves. J Thorac Cardiovasc Surg. 2018;156(1):197-206. doi:10.1016/j.jtcvs.2018.01.099.

These press releases may also interest you

at 02:16
Immunovia invites to a teleconference (in English) for investors, analysts and media on Thursday, August 20th, 2020 at 16:30 CET. Immunovia will publish the company's interim report on August 20th, 2020 at 16:00 CET. Mats Grahn, CEO will present...

at 02:05
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced the initiation of its Phase II programme evaluating its investigational gene therapy, GT005, for the treatment of geographic atrophy (GA) secondary to dry...

at 02:00
Utilizing Bluetooth Low Energy ("BLE") technology, Mobile Programming LLC has developed a COVID-19 Contact Tracing Application to help organizations get back to work safely, while addressing COVID-19 health and safety concerns. Because COVID-19 is...

at 01:36
"In June we successfully closed a $90m U.S. IPO on NASDAQ, which including the greenshoe that was exercised in July, resulted in gross proceeds of $97m in total. This successful and pioneering transaction, which was the first time a Swedish life...

at 01:21
Transaction adds late-stage orphan pipeline asset and platform in inflammation and fibrosis. Calliditas to acquire 62.7% of Genkyotex for ?20.3M in cash at ?2.80 per share in an off-market transaction. Following the closing of the control transaction...

at 01:10
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) accepted the company's supplemental Biologics License Application (sBLA) for a new self-administration option for...



News published on 16 july 2020 at 09:05 and distributed by: